The 36-month beta value for REPL is also noteworthy at 0.69. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for REPL is 62.53M, and at present, short sellers hold a 14.91% of that float. The average trading volume of REPL on July 09, 2025 was 1.25M shares.
REPL) stock’s latest price update
The stock of Replimune Group Inc (NASDAQ: REPL) has increased by 7.48% when compared to last closing price of $9.34.Despite this, the company has seen a gain of 9.71% in its stock price over the last five trading days. globenewswire.com reported 2025-06-06 that WOBURN, Mass., June 06, 2025 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.
REPL’s Market Performance
Replimune Group Inc (REPL) has experienced a 9.71% rise in stock performance for the past week, with a -3.29% drop in the past month, and a 34.03% rise in the past quarter. The volatility ratio for the week is 6.04%, and the volatility levels for the past 30 days are at 5.67% for REPL. The simple moving average for the past 20 days is 4.95% for REPL’s stock, with a -9.02% simple moving average for the past 200 days.
Analysts’ Opinion of REPL
ROTH MKM, on the other hand, stated in their research note that they expect to see REPL reach a price target of $17. The rating they have provided for REPL stocks is “Buy” according to the report published on August 28th, 2024.
Piper Sandler gave a rating of “Overweight” to REPL, setting the target price at $44 in the report published on April 17th of the previous year.
REPL Trading at 10.49% from the 50-Day Moving Average
After a stumble in the market that brought REPL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.95% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at REPL starting from Astley-Sparke Philip, who sale 32,279 shares at the price of $8.06 back on May 20 ’25. After this action, Astley-Sparke Philip now owns 1,405,071 shares of Replimune Group Inc, valued at $260,169 using the latest closing price.
Xynos Konstantinos, the Chief Medical Officer of Replimune Group Inc, sale 7,952 shares at $8.06 during a trade that took place back on May 20 ’25, which means that Xynos Konstantinos is holding 146,933 shares at $64,093 based on the most recent closing price.
Stock Fundamentals for REPL
The total capital return value is set at -0.47. Equity return is now at value -62.58, with -47.60 for asset returns.
Currently, EBITDA for the company is -261.63 million with net debt to EBITDA at 1.85. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.95.
Conclusion
In summary, Replimune Group Inc (REPL) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
